Cite
Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia.
MLA
Stein, Andrew M., et al. “Rapid Initial Decline in BCR-ABL1 Is Associated with Superior Responses to Second-Line Nilotinib in Patients with Chronic-Phase Chronic Myeloid Leukemia.” BMC Cancer, vol. 13, no. 1, June 2013, pp. 1–10. EBSCOhost, https://doi.org/10.1186/1471-2407-13-173.
APA
Stein, A. M., Martinelli, G., Hughes, T. P., Müller, M. C., Beppu, L., Gottardi, E., Branford, S., Soverini, S., Woodman, R. C., Hochhaus, A., Dong-Wook Kim, Saglio, G., & Radich, J. P. (2013). Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. BMC Cancer, 13(1), 1–10. https://doi.org/10.1186/1471-2407-13-173
Chicago
Stein, Andrew M., Giovanni Martinelli, Timothy P. Hughes, Martin C. Müller, Lan Beppu, Enrico Gottardi, Susan Branford, et al. 2013. “Rapid Initial Decline in BCR-ABL1 Is Associated with Superior Responses to Second-Line Nilotinib in Patients with Chronic-Phase Chronic Myeloid Leukemia.” BMC Cancer 13 (1): 1–10. doi:10.1186/1471-2407-13-173.